zilovertamab vedotin (MK-2140) / Merck (MSD)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zilovertamab vedotin (MK-2140) / Merck (MSD)
2021-003397-32: A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectiveness of medication MK-2140 in patients with Diffuse Large B Cell Lymphoma who failed prior therapies. Estudio de investigación en el que los participantes y personal sanitario saben qué tratamiento se está recibiendo, para evaluar la seguridad y eficacia de MK-2140 en pacientes con linfoma difuso de células B grandes que no hayan respondido a terapias anteriores.

Not yet recruiting
2
100
Europe, RoW
Zilovertamab Vedotin, MK-2140, Solution for injection
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., Merck Sharp & Dohme LLC., a subsidiary of Merck & Co.,Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC,
Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Tratamiento en participantes con linfoma difuso de células B grandes en recaída o resistente, Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s lymphoma, in patients who failed prior therapies) Linfoma difuso de células B grandes (un tipo de linfoma No Hodgkin) en pacientes que hayan fallado en terapias previas, Diseases [C] - Cancer [C04]
 
 
2021-005861-41: A research study to evaluate the safety and effectiveness and dosing of Zilovertamab Vedotin with R-CHP in adults with DLBCL Un estudio en investigación para evaluar la seguridad y eficacia y la dosificación de Zilovertamab Vedotin con R-CHP en adultos con LDCBG.

Ongoing
2
60
Europe
zilovertamab vedotin, Endoxan, Doxorubicin-Ebewe, Prednisone, Truxima, MK-2140, Lyophilisate for solution for infusion, Powder for solution for injection, Concentrate for solution for infusion, Tablet, Endoxan, Doxorubicin-Ebewe, Prednison 50 mg GALEN, Truxima
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Diffuse Large B-cell Lymphoma (DLBCL) Linfoma difuso de linfocitos B grandes (LDCBG), Phase II dose confirmation study in diffuse large B-cell lymphoma Estudio fase II de confirmación de dosis en Linfoma difuso de linfocitos B grandes., Diseases [C] - Cancer [C04]
 
 
2021-004450-36: A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malignancies Estudio para evaluar la seguridad y la eficacia de Zlovertamab Vedotin con o sin Nemtabrutinib y en aldultos con neoplasias malignas de linfocitos B.

Ongoing
2
260
Europe
Zilovertamab Vedotin, Nemtabrutinib, MK-2140, MK-1026, Lyophilisate for solution for infusion, Tablet
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Aggressive and Indolent B-cell Malignancies neoplasias linfoides B agresivas e indolentes, Phase II Signal Finding Study in B-Cell Malignancies Estudio de fase II de búsqueda de neoplasias linfoides B agresivas e indolentes., Diseases [C] - Cancer [C04]
 
 
MK-2140-002, NCT04504916: A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors

Completed
2
102
Canada, US
Zilovertamab vedotin, MK-2140, VLS-101
VelosBio Inc.
Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer, Progesterone-receptor-positive Breast Cancer, Estrogen-receptor-negative Breast Cancer, ER-negative Breast Cancer, Progesterone-receptor Negative Breast Cancer, PR-negative Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, PR-positive Breast Cancer, Platinum-resistant Ovarian Cancer, Gastric Cancer, Pancreatic Cancer
06/23
06/23
waveLINE-004, NCT05144841: A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

Active, not recruiting
2
140
Europe, Canada, US, RoW
MK-2140 (zilovertamab vedotin)
Merck Sharp & Dohme LLC
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
06/25
06/25
waveLINE-007, NCT05406401 / 2021-005861-41: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Recruiting
2
60
Europe, Canada, RoW
Zilovertamab Vedotin, MK-2140, VLS-101, Cyclophosphamide, CYTOXAN®, NEOSAR®, Doxorubicin, ADRIAMYCIN®, Rituximab, RITUXAN®, Rituximab Biosimilar, TRUXIMA®, Prednisone, Prednisolone
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Lymphoma, Large B-Cell, Diffuse (DLBCL)
01/26
01/26
waveLINE-006, NCT05458297 / 2021-004450-36: A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Recruiting
2
275
Europe, Canada, Japan, US, RoW
Zilovertamab vedotin, MK-2140, Nemtabrutinib, MK-1026
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
03/27
04/27
2020-004544-28: Phase 1/2 Substudy of Investigation Agents in PD-1/L1 Refractory Locally Advanced (Inoperable) or Metastatic Urothelial (Bladder) Cancer Subestudio de fase 1/2 de fármacos en investigación en el cáncer urotelial (vejiga) localmente avanzado (inoperable) o metastásico resistente a inhibidores de PD-1/L1

Not yet recruiting
1/2
40
Europe
Zilovertamab vedotin, MK-2140, Lyophilisate for solution for infusion
Merck Sharp & Dohme LLC, MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC
Locally advanced or metastatic urothelial cancer Cáncer urotelial localmente avanzado o metastásico, Locally Advanced (inoperable) or metastatic urothelial (bladder) cancer Cáncer urotelial (vejiga) localmente avanzado (inoperable) o metastásico, Diseases [C] - Cancer [C04]
 
 
LIGHTBEAM-U01, NCT06395103: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/)

Recruiting
1/2
90
RoW
Zilovertamab vedotin, MK-2140, VLS-101
Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
03/29
03/29
KEYMAKER-U04 substudy 04A, NCT05562830: A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Active, not recruiting
1/2
40
Europe, US, RoW
Zilovertamab vedotin, MK-2140, VLS-101
Merck Sharp & Dohme LLC
Urothelial Carcinoma
10/27
10/27

Download Options